Ollin Biosciences

Ollin Biosciences is an Austin-based clinical-stage biopharmaceutical company building a portfolio of best-in-disease therapies for vision-threatening eye diseases. Founded in 2023 and launched publicly in September 2025 with $100M in Series A financing, Ollin in-licenses validated drug candidates and races them through head-to-head trials against the market leaders. Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody for wet age-related macular degeneration and diabetic macular edema that posted superior anatomic results versus Roche's blockbuster Vabysmo in a Phase 1b study.